

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

NMC-G1

RRID:CVCL_1608

Type: Cell Line

Proper Citation

RRID:CVCL_1608

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1608

Proper Citation: RRID:CVCL_1608

Description: Cell line NMC-G1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Astrocytoma

Defining Citation: [PMID:8428960](#), [PMID:12068308](#), [PMID:16232199](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NMC-G1

Synonyms: NMCG-1, NMCG1, National Medical Center-Glioma 1

Cross References: CLO:CLO_0009897, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:967, BioSample:SAMN03472793, BioSample:SAMN10987927, cancercellines:CVCL_1608, Cell_Model_Passport:SIDM00575, CGH-DB:150-1, ChEMBL-Cells:ChEMBL3308842, ChEMBL-Targets:ChEMBL2366349, Cosmic:685874, Cosmic:908449, Cosmic:1746963, Cosmic:2302335, Cosmic:2367540, Cosmic-CLP:908449, DepMap:ACH-000200, EGA:EGAS00001000978, GDSC:908449, GEO:GSM326197, GEO:GSM887457,

GEO:GSM888537, GEO:GSM1670280, IARC_TP53:21587, JCRB:IFO50467, LiGeA:CCLE_668, LINCS_LDP:LCL-1385, Pharmacodb:NMCG1_1162_2019, PRIDE:PXD030304, Progenetix:CVCL_1608, PubChem_Cell_line:CVCL_1608, Wikidata:Q54930832

ID: CVCL_1608

Record Creation Time: 20220427T221345+0000

Record Last Update: 20260829T235453+0000

Ratings and Alerts

No rating or validation information has been found for NMC-G1.

No alerts have been found for NMC-G1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ayanlaja AA, et al. (2025) Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma. Neuro-oncology advances, 7(1), vda170.

Zhang M, et al. (2020) Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Frontiers in genetics, 11, 363.

Zhang M, et al. (2020) Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma. Frontiers in genetics, 11, 441.